Total raised
$41.5M
Last: Undisclosed 2024-04
Stage
Series B
Founded
2016
Headcount
17
HQ
Jerusalem
Sector
Health Tech & Life Sciences
About
SpliSense is a clinical stage company developing transformative RNA-based treatments for unmet needs relating to diverse pulmonary diseases. Its treatment is based on clinically validated Antisense Oligonucleotide (ASO) technology, delivered non-invasively by inhalation to the lungs.
The company is focused on a variety of innovative therapies, in different development stages from discovery to IND. Using an innovative approach, SpliSense aims to target the root cause of the disease, to overcome specific genetic mutations and modulate proteins expression and function.
The company recieved FDA approval for its lead ASO product, SPL84, for the treatment of patients with cystic fibrosis.
Funding history · 4 rounds · $41.5M total
2024-04
Undisclosed
$12.0M
2021-03
Series B
$28.5M
2020-02
Seed
Undisclosed
2018-11
Series A
$1.0M
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsGenes
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticalsBiotechnology
Business model
B2B
Highlights
1 Patents
Tags
medical-technologiespharma-companiespharmaceuticalsbiotechnologydrug-developmenttreatmentsgenetics